DM
Darren K. McGuire
Research areas: Medicine · Endocrinology, Diabetes and Metabolism · Diabetes Treatment and Management · Diabetes, Cardiovascular Risks, and Lipoproteins · Heart Failure Treatment and Management
0000-0002-6412-7989
Employment
Employment history is unavailable.
Education
Education history is unavailable.
Projects & Funding
Projects & funding information is unavailable.
Publications (59)
- PharmaPlain: SOUL trial looking at the effect of oral semaglutide on cardiovascular outcomes in people with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease Save
- Outcomes in patients with diabetes, atherosclerotic cardiovascular disease, and heart failure treated with tirzepatide or dulaglutide: SURPASS-CVOT analysis Save
- Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWIND Save
- SGLT Inhibitors for Heart and Kidney Disease in Type 1 Diabetes Save
- Response to Comment on Mann et al. Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial. Diabetes Care 2026;49:257–265 Save
- Association Between the 2022 AHA/ACC/HFSA Heart Failure Staging and Cardiovascular and Kidney Outcomes in Patients With Diabetes and Kidney Disease: A Post Hoc Analysis of the SCORED Randomized Controlled Trial Save
- Response to Comment on Lee et al. Comparative Efficacy of Glucagon-Like Peptide 1 Receptor Agonists for Cardiovascular Outcomes in Asian Versus White Populations: Systematic Review and Meta-analysis of Randomized Trials of Populations With or Without Typ… Save
- The Association Between Tirzepatide Versus Insulin Glargine and NT-proBNP Levels in People With Type 2 Diabetes With or at Elevated Risk for Cardiovascular Disease: Post hoc Analyses of SURPASS 4 Save
- Comparative Efficacy of Glucagon-Like Peptide 1 Receptor Agonists for Cardiovascular Outcomes in Asian Versus White Populations: Systematic Review and Meta-analysis of Randomized Trials of Populations With or Without Type 2 Diabetes and/or Overweight or … Save
- Recognized Outstanding Reviewers for Circulation in 2024 Save
- Is This the Real Life? Real-World Evidence of Empagliflozin in Health Care Resource Utilization and Cost Save
- Effects of an Intervention to Improve Evidence-Based Care for People With Diabetes and Cardiovascular Disease Across Sex, Race, and Ethnicity Subgroups: Insights From the COORDINATE-Diabetes Trial Save
- New Perspectives in Management of Cardiovascular Risk Among People With Diabetes Save
- Obesity and Cardiovascular Disease: A New Dawn Save
- Cardiovascular and Kidney Risks in Individuals With Type 2 Diabetes: Contemporary Understanding With Greater Emphasis on Excess Adiposity Save
- PREVENT Equations: A New Era in Cardiovascular Disease Risk Assessment Save
- Recognized Outstanding Reviewers for Circulation in 2023 Save
- Risk Factors for and Risk of Peripheral Artery Disease in Swedish Individuals With Type 2 Diabetes: A Nationwide Register-Based Study Save
- Impact of Ezetimibe on New‐Onset Diabetes: A Substudy of IMPROVE‐IT Save
- Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF Trials Save